Core Insights - Appili Therapeutics has secured a non-dilutive funding award of up to US$40 million from NIAID for the development of VXV-01, a dual-antigen vaccine targeting multidrug-resistant Candida species, highlighting the company's strategic partnerships and confidence in its execution [2][14] - The company has submitted multiple funding proposals to U.S. government agencies, with a potential combined value of approximately US$90 million, aimed at supporting critical development activities [3] - Appili has successfully re-launched LIKMEZ (ATI-1501) in the U.S. market, leading to increased sales and establishing a growing source of commercial revenue [8][9] Non-Dilutive Government Funding Strategy - Appili has secured over US$66 million in government contracts and grants, demonstrating the effectiveness of its non-dilutive funding model [4] - The company is well-positioned to advance its infectious disease and biodefense products while maintaining financial flexibility through public sector support [4] Product Development Updates - ATI-1801, a topical formulation for treating cutaneous leishmaniasis, is progressing towards NDA submission, with positive FDA feedback on its development strategy [5][6] - ATI-1701, a vaccine candidate for tularemia, has achieved key manufacturing milestones and is advancing towards IND submission with potential eligibility for a Priority Review Voucher [11][13] - The VXV-01 program is designed to address urgent needs in fungal infection prophylaxis, particularly for high-risk groups, and is supported by a significant government contract [15][16] Financial Performance - For the three months ending September 30, 2025, Appili reported a net loss of CAD 1.0 million, an increase from CAD 0.7 million in the same period in 2024, primarily due to reduced government assistance [18] - As of September 30, 2025, the company's cash balance was CAD 0.3 million, down from CAD 1.2 million as of March 31, 2025 [18]